Progress and Controversies in Gynecologic Oncology
prIME Conference
prIME Conference

Progress and Controversies in Gynecologic Oncology

2020 prIME Conference

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

This meeting has been canceled.

Join us in Barcelona for the Progress and Controversies in Gynecologic Oncology: 2020 prIME Conference to get the latest information on gynecologic malignancies from the world’s leading experts. The latest clinical trial data and practical information will be presented in an interactive format, fostering discussions that will impact clinical outcomes for your patients.

We look forward to welcoming you to the conference.


Andreas du Bois, MD, PhD
Nicoletta Colombo, MD
Jonathan Ledermann, BSc, MD, FRCP
Ignace Vergote, MD, PhD
Foto-Prof-du-Bois Colombo-150x150 ledermann-150x150 Ignace-Vergote

Date and Location

Friday, 24 January 2020
Saturday, 25 January 2020

Crowne Plaza Barcelona – Fira Center
Avda Rius i Taulet, 1-3
Barcelona, Spain



Friday, 24 January 2020
Saturday, 25 January 2020



Barcelona, Spain



9.0 European CME credits (ECMEC®s)

Friday, 24 January 2020

12:30 Welcome and Introduction
Andreas du Bois, MD, PhD

Session I: Cervical and Vulvar Cancers
Session Chairs: Nicoletta Colombo, MD, and Andreas du Bois, MD, PhD

12:40 Debate – Microinvasive Surgery in Cervical Cancer (LACC)
Moderator and case presentation: Andreas du Bois, MD, PhD
Pro: Henrik Falconer, MD, PhD
Contra: Pedro Ramirez, MD
13:25 Debate – Neoadjuvant Therapy for Cervical Cancer
Moderator and case presenter: Nicoletta Colombo, MD
Pro: Ignace Vergote, MD, PhD
Contra: TBD
14:10 Case Discussion – Vulvar Cancer With 1 Positive Lower Pelvic Lymph Node on MRI
Sven Mahner, MD, PhD

Session II: Endometrial Cancer and Rare Tumors
Session Chairs: Ignace Vergote, MD, PhD, and Jonathan Ledermann, MD, FRCP, FMedSci

14:40 State of the Art: Second-Line and Third-Line Treatment of Gestational Trophoblastic Neoplasia (GTN)
Michael Seckl, MD, PhD, FMedSci
15:10 Break
15:40 Debate – The Question of Lymph Node Staging: Surgically (SLN or Systematic) or Radiologically or None in Early-Stage Endometrial Cancer?
Moderator: Ignace Vergote, MD, PhD
Surgeon: TBD
Radiologist: Annika Loft Jakobsen, MD, PhD
16:25 Case Discussion – Using MMR and Other Molecular Factors to Guide Treatment of Endometrial Cancer
Koen Van de Vijver, MD, PhD
16:55 The Day After Laparoscopic Assisted Supracervical Hysterectomy (LASH): Oops! The Pathologist Says It’s Sarcoma – What to Do Now?
Christian Marth, MD, PhD
17:25 Day 1 Concluding Remarks and Adjourn

Saturday, 25 January 2020

08:30 Welcome and Introduction

Session III: First-Line Treatment of Ovarian Cancer
Session Chairs: Jonathan Ledermann, MD, FRCP, FMedSci, and Andreas du Bois, MD, PhD

08:35 Case Discussion – First-Line Management of the Patient With High-Grade Serous HRD-Positive Ovarian Cancer, FIGO IIIC, Primary Debulking With Macroscopically Complete Resection
Nicoletta Colombo, MD
09:05 Case Discussion -First-Line Management Following 3 Courses Carboplatin-Paclitaxel With a Good Response and Interval Debulking With Complete Resection in a Patient With an Undifferentiated HRD-Negative Ovarian Cancer FIGO IV B (1 Groin LN)
Antonio González-MartÍn, MD
09:35 Case Discussion – First-Line Management of a Patient With High-Grade Serous Ovarian Cancer FIGO IIIC, Primary Debulking but Post-Op Residual Tumor of at Least 1 cm (Diffuse Small Bowel) and Ascites
Isabelle Ray-Coquard, MD, PhD
10:05 Q&A and Discussion
10:15 Break

Session IV: Management of Recurrent Ovarian Cancer
Session Chairs: Nicoletta Colombo, MD, and Eric Pujade-Lauraine, MD, PhD

10:40 Case Discussion – Management of a Patient With BRCAwt HGSOC FIGO IIIA and First Relapse With a Platinum-Free Interval of 20 Months After 6 Cycles of Adjuvant Carboplatin-Paclitaxel: Anti-VEGF or PARP?
Jonathan Ledermann, MD, FRCP, FMedSci
11:10 Q&A and Discussion
11:15 Case Discussion – Management of a Patient With Recurrent High-Grade Serous Ovarian Cancer Following 2 Lines of Platinum-Based Chemotherapy Including First-Line Bevacizumab
Philipp Harter, MD, PhD
11:45 Q&A and Discussion
11:50 Case Discussion – Management of a Patient With Recurrent HRD-Positive Ovarian Cancer and a Platinum-Free Interval of 30 months, Previously Treated in ENGOT-ov19/PAOLA-1 (With Bevacizumab and a PARP Inhibitor)
Susana Banerjee, MA, MBBS, PhD, FRCP
12:10 Q&A and Discussion
12:15 Keynote Lecture: Combination Therapies With Targeted Agents in Ovarian Cancer
Domenica Lorusso, MD, PhD
12:45 Is There Still a Role for Surgery for Recurrent Ovarian Cancer? DESKTOP vs GOG213, or How to Select the Right Patient?
Andreas du Bois, MD, PhD
13:15 Break
13:30: Industry-Supported Satellite Symposium
14:45 Break

Session V: Treatment of Ovarian Cancer: The More Unusual Cases
Session Chairs: Ignace Vergote, MD, PhD, and Antonio González-MartÍn, MD

15:00 Update on the Treatment of Recurrent Low-Grade Serous Ovarian Carcinoma
15:30 Different Treatment Strategies for Early Ovarian Cancer: Lessons Learned From the ESGO-ESMO Consensus
Nicole Concin, MD, PhD
16:00 Keynote Lecture: How to Integrate All the Exciting New Drugs Into Treatment Strategies for Elderly or Frail Patients With High-Grade Serous Ovarian Cancer
Eric Pujade-Lauraine, MD, PhD
16:30 Day 2 Concluding Remarks and Adjourn
Ignace Vergote, MD, PhD



  • Andreas du Bois, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Jonathan A. Ledermann, MD, FRCP, FMed SciUCL Cancer Institute
    UCL Cancer Trials Centre
    London, United Kingdom
  • Ignace Vergote, MD, PhDUniversity Hospitals Leuven
    Leuven, European Union
  • Faculty

  • Susana Banerjee, MBBS, MA, PhD, FRCPRoyal Marsden Hospital
    Institute of Cancer Research
    London, United Kingdom
  • Nicole Concin, MD, PhDInnsbruck Medical University
    Innsbruck, Austria
  • Henrik Falconer, MD, PhDKarolinska Institutet
    Stockholm, Sweden
  • Antonio González-Martín, MD, PhDClínica Universidad de Navarra
    Madrid, Spain
  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Annika Loft Jakobsen, MD, PhDCopenhagen University Hospital
    Copenhagen, Denmark
  • Domenica Lorusso, MD, PhDFondazione IRCCS Istituto Nazionale dei Tumori di Milano
    Milan, Italy
  • Sven Mahner, MD, PhDUniversity of Munich
    Munich, Germany
  • Christian Marth, MD, PhDInnsbruck Medical University
    Innsbruck, Austria
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Pedro Ramirez, MDUniversity of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • Isabelle Ray-Coquard, MD, PhDCentre Léon Bérard
    Lyon, France
  • Michael Seckl, MD, PhD, FMedSciImperial College
    London, United Kingdom
  • Koren Van de VijverUniversity of Ghent
    Ghent, Belgium

To be confirmed

Registration Fees

Registration fees include VAT.
*Support documentation of eligibility may be required.

Your registration fee will include:

  • Access to all sessions and exhibition
  • Lunch and coffee breaks
  • Congress documentation

Registration Deadlines
Early registration rate: 22 December 2019 (23.59 CET)
Regular registration rate: 5 January 2020 (23.59 CET)

To Register
You may register online through 22 January 2020 at Registration confirmations will be issued upon successful completion of registration, and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than either 22 December 2019 (early registration rate) or 5 January 2020 (regular registration rate). Please register onsite after 22 January 2020.

Group Registrations
Group registrations will be accepted. For more information, please contact: [email protected].

Terms of Payment
All payments must be made in Euros. Payments can be made by credit card.

Registration will only be valid upon prIME, a Medscape Oncology Company’s receipt of full payment. Outstanding payment must be settled onsite by credit card.

To receive a refund of registration fees, written notice of cancellation must be received at [email protected].

The following deadlines and cancellation fee schedule will apply:

  • Before 2 December 2019: €50 administrative charge
  • From 2 December 2019 — 21 December 2019: 60% cancellation fee applies on registration fee(s)
  • From 22 December 2019: 100% cancellation fee applies on registration fee(s)
  • Name changes from 22 December 2019: €15 fee is charged per change

Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 22 December 2019.

prIME, a Medscape Oncology Company does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

A limited number of rooms are available at the Crowne Plaza Barcelona – Fira Center (meeting venue). Please make sure to make your bookings as quickly as possible through our online registration form.

Crowne Plaza Barcelona – Fira Center
Avenida Rius i Taulet, 1-3
Barcelona, Spain
Tel: +34 934 262 223

Check in time: 15.00
Check out time: 12.00

Double room for single occupancy €189, including breakfast and VAT
Double standard room €209, including breakfast and VAT

Room Booking

You can book your hotel room via the online registration form by clicking on the “Register Me” button.

Cancellation Fee Hotel Rooms

A cancellation fee may apply in the event that a delegate cancels his/her (registration and) hotel accommodation. A written notice of cancellation must be received at [email protected].

  • Until 15 October 2019: 60% of the total amount due is nonrefundable
  • From 16 October 2019: 100% of the total amount due is nonrefundable
  • From 22 December 2019: A modification fee of €15 applies for all changes

The amount of hotel room fees remitted will be refunded after the Conference. Substitutions are accepted with written notification. In case of no-shows a 100% cancellation fee of the entire stay will apply.

All inquiries related to the Progress and Controversies in Gynecologic Oncology: 2020 prIME Conference may be addressed to [email protected].

Schenkkade 50S
2595 AR The Hague
the Netherlands

Tel.: + 31 70 30 67 190
Fax: + 31 70 33 18 335

Most EU citizens only need their national identity card or passport to enter Spain. Non-EU citizens require a valid passport to enter Spain, but many countries are exempt from tourist visas. It is essential that you check with the Spanish embassy or consulate in your country before travelling. Without exception, passports must be valid for at least six months after your planned date of departure from Spain.

prIME, a Medscape Oncology Company will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

Note: Passport and visa requirements are liable to change at short notice. Travelers are advised to check their entry requirements with their embassy or consulate.

From Barcelona’s main international airport El Prat you can travel different ways to the Conference venue:

TAXI: Barcelona has 11,500 taxis easily identified by their yellow and black color. It takes 15-20 minutes to get to the venue, depending on traffic.

AEROBUS: This special service is clearly signposted at the stops outside the terminal and it takes you to different parts of the city. The Plaza de España stop is the closest to the hotel, approximately a 5-minute walk from the stop to the hotel.

TRAIN: The station is located to the west of the terminal. Trains go to Sants station. From here you can take either the metro 2 stops to Plaza de España and then a 10-15 minute walk or you can take a taxi.

CAR: Take the Castelldefels motorway (C-31) toward Barcelona to Plaza de España. Turn right on Avenida Maria Cristina and drive until you see the National Palace. Turn left on Avenida Rius i Taulet and carry on straight until Lleida Street. The hotel is right on the corner.

Barcelona has a very good public transport system (TMB), with special ten-trip and one-day, two-day, and three-day tickets available for bus, metro, and local trains. You can call a taxi or flag them down in the streets. In many taxis you can also pay by credit card.

Barcelona has a Mediterranean climate with mild, sunny winters, warm summers, and relatively low rainfall. In January, the average temperature is 13° Celsius (55.4° Fahrenheit).

Barcelona is in the Central European time zone (GMT +1).

Spanish and Catalan are the two main languages spoken in Barcelona. English is also widely spoken and to some extent French and German.

The Spanish currency is the Euro (€).

Value-added tax, or VAT, is otherwise known as IVA (impuesto sobre el valor añadido). The IVA is 10% on accommodation and restaurant prices and is usually, but not always, included in quoted prices. On retail goods the IVA is 21%. IVA-free shopping is available in duty-free shops at all airports for people travelling between EU countries.

Tips are already included in restaurant bills, but it is customary to round up an extra 5% to 10% if you are satisfied with the service. Porters are generally tipped €1 per bag.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Management of vulvar, cervical, and endometrial cancers
    • Standard and emerging therapies for ovarian cancer, and how these options impact patient outcomes
  • Have greater competence related to
    • Selection of optimal treatment regimens for patients with gynecologic malignancies, taking into account patient and disease characteristics
  • Demonstrate greater confidence in their ability to
    • Effectively manage patients with gynecologic malignancies

This educational activity is supported by:



Exhibiting at this conference is possible. For more information, please contact Stephen Dunn by email at [email protected].

Independent Medical Education (IME)

Progress and Controversies in Gynecologic Oncology: 2020 prIME Conference held in Barcelona, Spain on 24 January 2020 – 25 January 2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.


This activity is provided by prIME, a Medscape Oncology Company.


Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.